Mechanisms and significance of liver steatosis in hepatitis C virus infection

被引:108
作者
Negro, Francesco
机构
[1] Hop Univ, Serv Gastroenterol & Hepatol, CH-1205 Geneva, Switzerland
[2] Hop Univ, Serv Pathol Clin, CH-1205 Geneva, Switzerland
关键词
hepatitis C; fibrosis; insulin resistance; insulin signaling;
D O I
10.3748/wjg.v12.i42.6756
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The pathogenesis of liver damage associated with chronic hepatitis C virus (HCV) infection is thought to be largely immunomediated. However, some frequent histopathological features, such as steatosis, suggest a direct cytopathic effect of HCV. The direct responsibility of HCV in the pathogenesis of steatosis is shown by: (1) the association with HCV genotype 3 infection, suggesting that some viral sequences are involved in the intracellular accumulation of lipids; (2) the correlation between severity of steatosis and HCV replication levels; (3) association between response to treatment and disappearance of steatosis. Experimental studies have shown that the nucleocapsid protein of HCV (core protein) is capable and sufficient to induce lipid accumulation in hepatocytes. Moreover, the observation that chronic hepatitis C patients have reduced serum levels of ApoB suggests an interference with the very-low density lipoprotein (VLDL) assembly, although other mechanisms are possible. In patients with sustained virological response induced by antiviral therapy, such levels are normalized. Other observations suggest that the pathogenesis of steatosis in chronic hepatitis C is not solely due to HCV. The origin of the mild steatosis observed in most patients may be metabolic, since its severity correlates with body mass index and insulin resistance. Most studies have shown a correlation between presence and/or severity of steatosis and fibrosis stage, but it is unclear whether this effect is direct or mediated by the associated insulin resistance, increased susceptibility to apoptosis, or by inflammatory cytokines. Finally, steatosis negatively influences the rate of response to antiviral treatment, as confirmed by large clinical trials. Management of steatosis in chronic hepatitis C requires knowledge of its pathogenesis and may involve both life-style changes and pharmacological interventions, although the latter remain largely experimental. (C) 2006 The WJG Press. All rights reserved.
引用
收藏
页码:6756 / 6765
页数:10
相关论文
共 96 条
[1]   2 CASES FROM THE SPECTRUM OF NONALCOHOLIC STEATOHEPATITIS [J].
ABDELMALEK, M ;
LUDWIG, J ;
LINDOR, KD .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1995, 20 (02) :127-130
[2]   An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation [J].
Abid, K ;
Pazienza, V ;
de Gottardi, A ;
Rubbia-Brandt, L ;
Conne, B ;
Pugnale, P ;
Rossi, C ;
Mangia, A ;
Negro, F .
JOURNAL OF HEPATOLOGY, 2005, 42 (05) :744-751
[3]   Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity [J].
Adinolfi, LE ;
Gambardella, M ;
Andreana, A ;
Tripodi, MF ;
Utili, R ;
Ruggiero, G .
HEPATOLOGY, 2001, 33 (06) :1358-1364
[4]   Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C [J].
Adinolfi, LE ;
Ingrosso, D ;
Cesaro, G ;
Cimmino, A ;
D'Antò, M ;
Capasso, R ;
Zappia, V ;
Ruggiero, G .
HEPATOLOGY, 2005, 41 (05) :995-1003
[5]   Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors [J].
Akuta, N ;
Suzuki, F ;
Tsubota, A ;
Suzuki, Y ;
Someya, T ;
Kobayashi, M ;
Saitoh, S ;
Arase, Y ;
Ikeda, K ;
Kumada, H .
JOURNAL OF HEPATOLOGY, 2002, 37 (06) :831-836
[6]   Review article: chronic hepatitis C - natural history and cofactors [J].
Alberti, A ;
Vario, A ;
Ferrari, A ;
Pistis, R .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 :74-78
[7]   Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells [J].
Aleffi, S ;
Petrai, I ;
Bertolani, C ;
Parola, M ;
Colombatto, S ;
Novo, E ;
Vizzutti, F ;
Anania, FA ;
Milani, S ;
Rombouts, K ;
Laffi, G ;
Pinzani, M ;
Marra, F .
HEPATOLOGY, 2005, 42 (06) :1339-1348
[8]   EVIDENCE FOR A LINK BETWEEN HEPATITIS-C VIRUS-INFECTION AND DIABETES-MELLITUS IN A CIRRHOTIC POPULATION [J].
ALLISON, MED ;
WREGHITT, T ;
PALMER, CR ;
ALEXANDER, GJM .
JOURNAL OF HEPATOLOGY, 1994, 21 (06) :1135-1139
[9]   Characterization of low- and very-low-density hepatitis C virus RNA-containing particles [J].
André, P ;
Komurian-Pradel, F ;
Deforges, S ;
Perret, M ;
Berland, JL ;
Sodoyer, M ;
Pol, S ;
Bréchot, C ;
Paranhos-Baccalà, G ;
Lotteau, V .
JOURNAL OF VIROLOGY, 2002, 76 (14) :6919-6928
[10]   Steatosis in chronic hepatitis C: Why does it really matter? [J].
Asselah, T ;
Rubbia-Brandt, L ;
Marcellin, P ;
Negro, F .
GUT, 2006, 55 (01) :123-130